Compare JPMorgan Equity Premium Income ETF (JEPI) vs Medpace Holdings Inc (MEDP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
JPMorgan Equity Premium Income ETF vs Medpace Holdings Inc — how do they compare? JPMorgan Equity Premium Income ETF trades at $56.79 (market cap $45.55B), while Medpace Holdings Inc trades at $617.65 (market cap $16.82B). The key difference: JPMorgan Equity Premium Income ETF is far larger — about 2.7× Medpace Holdings Inc's market cap, and Medpace Holdings Inc is trading nearer its 52-week high, JPMorgan Equity Premium Income ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold JPMorgan Equity Premium Income ETF for 57 Days and Medpace Holdings Inc for 14 Days on average.
| JEPI | MEDP | |
|---|---|---|
Market Cap | $45.55B | $16.82B |
Volume | 3,820,809 | 223,093 |
Sector | Income / Options Overlay | Health |
52-Week High | $59.88 | $630.19 |
52-Week Low | $55.29 | $393.42 |
Typical Hold Time | 57 Days | 14 Days |
Enterprise Value | — | $16.44B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JEPI trades at $56.73, up 0.5% with a bearish technical signal from moving averages. The ETF maintains consistent monthly dividend distributions, with recent payments of $0.37 in August and July 2026. Technical indicators show neutral oscillators with key support at $56 and resistance at $57. Recent news highlights JEPI's role in income strategies and institutional interest.
The covered-call strategy provides income but may limit upside during rallies. Institutional ownership growth signals confidence, though the bearish technical outlook and income-focused strategy suggest moderate growth potential with steady dividend income as the primary appeal.
Medpace (MEDP) trades at $617.47, up 2.19% with strong quarterly earnings beats and robust profitability metrics. The stock shows neutral technical signals with key resistance at $620, while fundamentals reveal impressive ROE of 162.15% and consistent revenue growth to $2.8B projected for 2026. Recent CEO stock sales and mixed institutional activity create balanced sentiment ahead of Q3 earnings announcement on October 21, 2026.
MEDP presents growth potential with analyst consensus target of $620.44 and strong historical execution, though elevated valuations (P/E 35.41) and insider selling warrant caution. The stock's upside depends on continued earnings delivery amid competitive medical services landscape.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About JPMorgan Equity Premium Income ETF
JEPI is an actively managed ETF that seeks to deliver monthly income and stock market exposure with lower volatility. It combines an equity portfolio with an options strategy to generate steady premiums.
Read more on JEPI →About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →
